Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.

Mark W Linder1, Stephen Looney, Jesse E Adams

  • 1Department of Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY 40292, USA. mwlind01@gwise.louisville.edu

Journal of Thrombosis and Thrombolysis
|August 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR.

Molecular diagnosis & therapy·2026
Same author

Laboratory Medicine Approaches for Assessing Delayed Graft Function in Renal Transplant.

The journal of applied laboratory medicine·2026
Same author

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.

Molecular diagnosis & therapy·2026
Same author

Using Stakeholder Engagement to Build Cancer Survivorship Care Coordination Capacity Between Primary and Oncology Care.

Health equity·2026
Same author

Evaluation of turnaround times and performance of in-house ChromaCode high-definition PCR compared to send-out next-generation sequencing in non-small cell lung cancer.

American journal of clinical pathology·2025
Same author

Rigorous validation of machine learning in laboratory medicine: guidance toward quality improvement.

Critical reviews in clinical laboratory sciences·2025

Warfarin dosing is complex due to genetic variations. Cytochrome P450 2C9 (CYP2C9) genotype influences warfarin metabolism, affecting required doses. Understanding CYP2C9 genotype and age aids in personalized warfarin therapy.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Drug Metabolism

Background:

  • Warfarin dosing presents challenges due to unpredictable patient responses.
  • Genetic variations in Cytochrome P450 2C9 (CYP2C9) are linked to warfarin hypersensitivity.
  • CYP2C9 metabolizes the active S-enantiomer of warfarin, influencing drug efficacy.

Purpose of the Study:

  • To investigate the relationship between CYP2C9 genetic variations (genotype) and their functional impact (phenotype).
  • To establish a foundation for interpreting CYP2C9 genotype to guide warfarin dosage adjustments.
  • To characterize how CYP2C9 genotype affects warfarin pharmacokinetics and pharmacodynamics.

Main Methods:

  • Genotyping for CYP2C9*2, *3, and *5 alleles using PCR and restriction digestion.

Related Experiment Videos

  • Phenotypic assessment included warfarin dose, S-warfarin clearance, and S:R-warfarin ratio.
  • Analysis of patients stabilized on warfarin therapy at an anticoagulation clinic.

    • Main Results:

    • CYP2C9*2 and *3 alleles were associated with lower warfarin maintenance doses.
    • Variant CYP2C9 alleles led to decreased S-warfarin oral clearance and increased S:R-warfarin ratio.
    • Age impacted warfarin dose requirements in individuals with the common CYP2C9*1/*1 genotype but not in those with variant alleles.

    Conclusions:

    • Plasma S-warfarin concentrations were similar across different CYP2C9 genotypes in patients at a stable INR.
    • Warfarin dose requirements vary based on S-warfarin clearance, which is reduced by CYP2C9*2 and *3 alleles.
    • CYP2C9 genotype and patient age are valuable factors for refining warfarin dosage ranges.